702 related articles for article (PubMed ID: 17320799)
41. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
42. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
[TBL] [Abstract][Full Text] [Related]
43. Influence of genetic polymorphism in matrix metalloproteinase-3 on extent of coronary atherosclerosis and risk of coronary artery stenosis.
Seifi M; Fallah S; Firoozrai M
Arch Med Res; 2009 Oct; 40(7):600-4. PubMed ID: 20082876
[TBL] [Abstract][Full Text] [Related]
44. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
45. [The role of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinaes-1 in chronic obstructive pulmonary disease].
Xu XM; Sun TY; Lin JB; Zhang HS
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1138-41. PubMed ID: 12921631
[TBL] [Abstract][Full Text] [Related]
46. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
[TBL] [Abstract][Full Text] [Related]
47. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
[TBL] [Abstract][Full Text] [Related]
48. [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma].
Lu ZQ; Wang YM; Cao YY; Zhang QJ; Zhang XH; Li YH; Wang HS; Xie HL; Jiao BH; Zhang JH
Ai Zheng; 2007 May; 26(5):463-8. PubMed ID: 17672933
[TBL] [Abstract][Full Text] [Related]
49. [Association between serum matrix metalloproteinase-3 concentration and the promoter 5A/6A polymorphism in patients with coronary heart disease].
Gao B; Li ZC
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Sep; 16(9):536-9. PubMed ID: 15355616
[TBL] [Abstract][Full Text] [Related]
50. Analysis of the MMP-9 (C-1562 T) and TIMP-2 (G-418C) gene promoter polymorphisms in patients with chronic periodontitis.
de Souza AP; Trevilatto PC; Scarel-Caminaga RM; de Brito RB; Barros SP; Line SR
J Clin Periodontol; 2005 Feb; 32(2):207-11. PubMed ID: 15691353
[TBL] [Abstract][Full Text] [Related]
51. Proteolytic and cytokine balance abnormalities in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass.
Paśnik J; Moll J; Cywińska-Bernas A; Moll J; Sysa A; Zeman K
Kardiol Pol; 2007 Oct; 65(10):1208-14; discussion 1215. PubMed ID: 17979049
[TBL] [Abstract][Full Text] [Related]
52. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
[TBL] [Abstract][Full Text] [Related]
53. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
54. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease].
Chen R; Zhang AR; Zhao XX; Li ZH
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606
[TBL] [Abstract][Full Text] [Related]
55. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
56. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
Marson BP; Lacchini R; Belo V; Dickel S; da Costa BP; Poli de Figueiredo CE; Tanus-Santos JE
Am J Nephrol; 2012; 35(3):209-15. PubMed ID: 22302011
[TBL] [Abstract][Full Text] [Related]
57. Changes in the concentration of plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) after total joint replacement in patients with arthritis.
Omura K; Takahashi M; Omura T; Miyamoto S; Kushida K; Sano Y; Miura M; Nagano A
Clin Rheumatol; 2002 Nov; 21(6):488-92. PubMed ID: 12447632
[TBL] [Abstract][Full Text] [Related]
58. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
Szczepańska-Kostro J; Kowalewski M; Urban M; Gardziejczyk M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(4):257-60. PubMed ID: 17239302
[TBL] [Abstract][Full Text] [Related]
59. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
60. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Pawlak K; Pawlak D; Mysliwiec M
Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
